Skip to main content
. 2019 Jul 15;129(8):3324–3338. doi: 10.1172/JCI126022

Figure 8. PD-L1 Y112F mutation reduces PD-L1 expression in Hepa 1-6 without affecting tumorigenesis in immunodeficient mice.

Figure 8

(A) WB analysis of exogenous PD-L1 expression in FLAG–PD-L1 WT or Y112F–Hepa 1-6 cells with or without exposure to IL-6 (20 ng/mL) and/or ruxolitinib (10 μmol/L) for 18 hours. Data show relative fold change of PD-L1 protein normalized to the mock group (1 or 4) in each cell line (n = 3). (B) Tumor growth of PD-L1 WT–Hepa 1-6 or Y112F–Hepa 1-6 cells in immunodeficient (NSG) mice (n = 6). (C) Tumor weight (left) and images of tumors (right) harvested from NSG mice inoculated with PD-L1 WT–Hepa 1-6 or Y112F–Hepa 1-6 cells. Scale bar: 1 cm. (D) Flow cytometric analysis of cell surface PD-L1 expression on PD-L1 WT–Hepa 1-6 or Y112F–Hepa 1-6 tumors (n = 5). The relative fold change in the MFI of PD-L1 is shown. Error bars represent ± SD. ***P < 0.001, ****P < 0.0001, 1-way ANOVA (A), repeated-measures ANOVA (B), and Mann-Whitney test (C and D).